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Objective To determine the effect of moxiﬂoxacin on secretion of cytokines by human
monocytes stimulated with lipopolysaccharide (LPS) or Pansorbin.
Methods Monocytes obtained from 10 healthy volunteer donors were stimulated with
LPS or Pansorbin and exposed or not to different concentrations of the ﬂuoroquinolone
antibiotic moxiﬂoxacin. At 3, 6 and 24 h, the amounts of interleukin-1a (IL-1a), IL-1b, IL-6,
IL-10, IL-12 (p70) and tumour necrosis factor-a (TNF-a) were measured in the super-
natants of the monocyte cultures using enzyme-linked immunosorbent assay.
Results Stimulation of human monocytes with either LPS or Pansorbin resulted in a
signiﬁcant increase in secretion of each of the cytokines examined. Treatment of LPS-
stimulated monocytes with moxiﬂoxacin signiﬁcantly inhibited (P< 0.01) secretion of IL-
1a by monocytes of each of 10 human donors; the secretion of TNF-a was signiﬁcantly
inhibited (P< 0.01) in monocytes from six of 10 donors. In general there was a trend
towards inhibition of secretion of IL-6, IL-10 and IL-12 (p70), but the inhibitory effect was
not statistically signiﬁcant. Secretion of cytokines by Pansorbin-stimulated monocytes
was not signiﬁcantly inhibited by moxiﬂoxacin.
Conclusions Moxiﬂoxacin has immunomodulatory activity through its capacity to alter
the secretion of IL-1a and TNF-a by human monocytes.
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INTRODUCTION
A number of antibiotics have been found to have
signiﬁcant immunomodulatory properties both
in vitro and in vivo in animal models [1–4]. Such
properties may have clinical signiﬁcance for the
modulation of the immune response of patients,
including those who are immunodeﬁcient, and
those who have inﬂammatory diseases including
septic shock. Thus, antibiotics may play a dual
role in infections, an antimicrobial effect and an
effect on either the beneﬁcial or the detrimental
host response per se [1,5]. The increasing evidence
for the role of cytokines and chemokines in the
severity of, or even death due to, infection [6–8]
indicates the importance of deﬁning the immuno-
modulatory activity of antibiotics and other drugs
used to treat patients with infection. Among the
mechanisms bywhich the immune systemcombats
invasion by pathogens, the role played bymultiple
cytokines working in concert is becoming increas-
ingly recognized. It has also become apparent that
in the infected host, excessive or unrestricted
activity of certain cytokines can be detrimental
as, for example, occurs in toxic shock syndrome.
Potentially harmful effects of T cells and macro-
phages can be prevented by down-regulatory, anti-
inﬂammatory, cytokines [6]. Lack of such control, as
in mice with targeted disruption of interleukin-10
(IL-10) andToxoplasma gondii infection, can result in
a ‘cytokine storm’ that causes tissue injury and
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death of the host [9,10]. The ﬂuoroquinolone
moxiﬂoxacin (1-cyclopropyl-7-(2,8-diazabicyclo
[4.3.0]nonane)-6-ﬂuoro-8-methoxy-1,4-di-hydro-
4-oxo-3-quinoline carboxylic acid hydrochloride)
has potent antimicrobial activity against both
Gram-negative and Gram-positive bacteria [11–
13]. Our interest in the role of cytokines in the
immunopathogenesis of infection [10,14], as well
as our demonstration of the capacity of certain
antibiotics to modulate the production of cyto-
kines by human monocytes [3,4,15], prompted
us to study the effects of moxiﬂoxacin on the
in vitro production of cytokines by puriﬁed human
peripheral blood monocytes (PBMC).
METHODS
Reagents
Moxiﬂoxacin (Bay 12-8039, batch 502610) was
obtained from Bayer Corp., West Haven, CT.
The drug stock solution and further dilutions were
made in RPMI-1640 medium. Lipopolysaccharide
(Escherichia coli O26:B6, LPS) was purchased from
Difco Laboratories, Detroit, MI. Pansorbin, heat-
killed Staphylococcus aureus Cowan strain I (SAC)
cells were purchased from Calbiochem-Behring
Co., La Jolla, CA.
Isolation of monocyte-enriched PBMC
Blood was obtained by venepuncture from seven
male and three female healthy donor volunteers
(ages from 20 to 57 years). Written authorized
consent was obtained from each donor. PBMC
were obtained and cultured as previously
described [15]. Brieﬂy, cells were separated on
Ficoll–Paque (Pharmacia Biotech AB, Uppsala,
Sweden) density gradients, washed twice with
calcium- and magnesium-free phosphate-buffered
saline (PBS; Mediatech, Inc., Herndon, VA) and
fractionated by centrifugation over discontinuous
Percoll (Pharmacia Biotech AB, Uppsala, Sweden)
gradients. The monocyte-enriched cell fraction
was collected, washed with calcium- and magne-
sium-free PBS, and resuspended in RPMI-1640
(with 25mM HEPES, L-glutamine; Mediatech,
Inc., Herndon, VA) containing 10% fetal bovine
serum (FBS; GIBCO BRL Products, Grand Island,
NY) at a cell density of 1 106 cells/mL.
Characterization of the monocytes was with the
Naphthol AS-D Chloroacetate Esterase and a-
Naphthyl Acetate Esterase kit (Sigma Diagnostics,
St Louis, MO) to demonstrate the a-naphthyl acet-
ate esterase enzyme within monocytes. Under the
conditions of the assay, the enzyme is detected
primarily in monocytes, macrophages and histio-
cytes and is virtually absent in granulocytes [16].
Lymphocytesmay occasionally exhibit weak activ-
ity [17]. At least 90% of the cells used in each
experiment in the present study were identiﬁed
as monocytes.
In vitro cytokine assays
Cells were seeded into 24-well plates (Costar Cor-
poration, Cambridge, MA.) at a cell density of
1 106 cells/mL (1mL per well) and incubated
in the presence of 100 ng/mL of LPS or 0.0075%
(wt/vol.) of Pansorbin with or without 1, 5, or
10mg/L of moxiﬂoxacin for 3, 6, or 24 h at 37 8C in
a 5% CO2 incubator. Cell-free supernatants were
recovered by centrifugation and stored at 20 8C
until assayed. The concentration of each cytokine
[IL-1a, IL-1b, IL-6, IL-10, IL-12 (p70), tumour
necrosis factor-a (TNF-a)] was determined by
enzyme-linked immunosorbent assay (ELISA)
with commercially available reagents (PharMin-
gen, San Diego, CA). The concentration of IL-1b
was determined by ELISA with matched antibody
pairs and supporting reagents from ENDOGEN
(Weburn, MA). Quantiﬁcation was performed on
the basis of a standard curve derived by linear
dilution of the cytokine standards included in the
respective kits. The detection limit for IL-1a and
IL-10 was 8 pg/mL, for IL-6 and TNF-awas 20pg/
mL, and for IL-1b was 3.9 pg/mL. In reproduci-
bility assays for each cytokine the coefﬁcient of
variation (%CV) was <12% in replicate assays
from the same sample. Cytokine assays were per-
formed in quadruplicate, using the supernatant
samples or appropriate dilutions of the superna-
tants as determined in preliminary studies.
Cellular toxicity assay
Toxicity of moxiﬂoxacin for the puriﬁed mono-
cytes was determined by the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
cytotoxicity assay using Cell Titer 96 Kit (MTT
assay, Promega Corp., Madison, WI). Brieﬂy, cells
were plated in quadruplicate wells at 1 103 cells/
well. Following a 4-h incubation at 37 8C in a 5%
CO2 incubator, moxiﬂoxacin in various concentra-
tions was added. Four hours before the time-point
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at 24 h, 16 mL of the dye indicator solution was
added. Following an additional 4-h incubation,
100 mL of the solubilization/stop solution was
added to each well. One hour later, the plates were
read for absorbency at 570 nm in an automatic
ELISA plate reader. The results were quantiﬁed
as the optical density at 570 nm of cultures exposed
to moxiﬂoxacin or exposed to the diluent alone.
Statistics
All values were expressed as means standard
deviations. Welch’s test, which does not assume
a similar distribution of variances, was used to
determine statistical differences. A P 0.05 was
considered statistically signiﬁcant.
RESULTS
Individual variation in the secretion of each cyto-
kine was observed following stimulation of the
monocytes with LPS or Pansorbin. Treatment of
monocytes with LPS resulted in a signiﬁcant
(P< 0.001) increase in accumulation of each of
the cytokines in the cell culture supernatants.
Figure 1(a,b) shows the combined representative
results of monocytes from three donors with IL-1a
and TNF-a, respectively. Secretion of IL-1a (Figure
1a) increased progressively over the 24-h study
period whereas the highest amount of TNF-a (Fig-
ure 1b) was observed at 6 h. Secretion of IL-1b
followed the same pattern as IL-1a, IL-6 was high-
est after 6 and 24 h of exposure and IL-4, IL-10 and
IL-12 were secreted at each of the three time
periods (data not shown). Treatment of monocytes
with Pansorbin also resulted in a signiﬁcant
increase in the secretion of each cytokine (data
not shown).
Exposure of LPS-stimulated monocytes to the
three concentrations of moxiﬂoxacin resulted in
signiﬁcant (P< 0.01) inhibition of secretion of IL-
1a in all 10 donors, of IL-1b in one of 10 donors
(P< 0.05) and of TNF-a in six of 10 donors
(P< 0.05). Secretion of IL-4, IL-6, and IL-12 (P70)
by LPS-stimulated monocytes was not signiﬁ-
cantly inhibited by treatment with any of the
concentrations of moxiﬂoxacin. Inhibition of secre-
tion of IL-1a (Figure 2a) occurred 6 and 24 h fol-
lowing treatment with each concentration of
moxiﬂoxacin, whereas inhibition of secretion of
TNF-a (Figure 2b) occurred mainly after 6 h of
exposure to the antibiotic. The highest concen-
tration of moxiﬂoxacin (10mg/L) signiﬁcantly
(P< 0.05) inhibited TNF-a at each time period. In
LPS-treated monocytes of four donors, secretion of
TNF-a was not signiﬁcantly inhibited. Treatment
with moxiﬂoxacin of LPS-stimulated monocytes of
two of the latter donors resulted in a signiﬁcant
(P< 0.05) increase in the secretion of TNF-a (data
not shown). Although the pattern of inhibition of
secretion of IL-1b was similar to that observed for
IL-1a, the differences in the amounts of IL-1b
Figure 1 In vitro secretion of IL-1a (a) and TNF-a (b) by
LPS-stimulated or -unstimulated human monocytes at 3, 6
or 24 h. LPS stimulation resulted in a significant increase in
the secretion of these cytokines by monocytes of all 10
donors. The figures show the combined results of mono-
cytes from three representative donors.
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secreted by LPS-stimulated monocytes and by
LPS-stimulated monocytes treated with moxiﬂox-
acin reached statistical signiﬁcance in the mono-
cytes from only one donor (data not shown).
Treatment of Pansorbin-stimulated monocytes
with moxiﬂoxacin resulted in signiﬁcant (P< 0.05)
inhibition of secretion of TNF-a in monocytes
from only one of 10 individuals. Secretion of
IL-a, IL-1b, IL-6, IL-10 and IL-12 (P70) by Pansor-
bin-stimulated monocytes was not signiﬁcantly
affected by exposure to any of the concentrations
of moxiﬂoxacin.
Toxicity of moxiﬂoxacin for the cultured mono-
cytes was not noted at any of the concentrations
used as determined by the MTT assay.
DISCUSSION
Monocytes were employed in our studies because
of their critical role in the early cytokine response
to a number of pathogens and/or their products
which serve as major mediators of the acute
inﬂammatory response [18,19]. Our results re-
vealed that stimulation of monocytes with LPS
alone or with Pansorbin alone resulted in a sig-
niﬁcant increase in accumulation of each of the
examined cytokines in the supernatants of the
cultured monocytes. Although treatment of LPS-
stimulated monocytes with moxiﬂoxacin inhibited
secretion of most cytokines, the same treatment
did not have a demonstrable effect on cytokine
secretion by Pansorbin-stimulated monocytes.
This observation may be explained by the fact that
LPS and Staphylococcus aureus, Cowan strain, use
different intracellular pathways to induce cytokine
production by human monocytes [20]. It is also
possible that moxiﬂoxacin may directly interact
with LPS, its receptors and/or its stimulatory
pathway to inhibit cytokine secretion. The inhibi-
tory effect of moxiﬂoxacin was most pronounced
for IL-1a and TNF-a. In general, there was a trend
towards inhibition of secretion of each of the
cytokines but statistical signiﬁcance was achieved
only for these two cytokines. This is in contrast to
previous observations [15] with another ﬂuoroqui-
nolone, trovaﬂoxacin, which signiﬁcantly in-
hibited secretion of IL-1a, IL-1b, IL-6, IL-10,
granulocyte–macrophage colony-stimulating fac-
tor and TNF-a by monocytes stimulated either
with LPS or Pansorbin. The reason for this differ-
ence is unclear. In humans, a single dose of 50mg
or 800mg of moxiﬂoxacin results in plasma levels
of 0.29mg/L and 4.73mg/L, respectively, after
0.5–4 h of administration [11]. Concentrations
within this range were examined in this study.
Moxiﬂoxacin signiﬁcantly inhibited secretion of
TNF-a in LPS-stimulated monocytes of 6 of 10
donors. Inhibition occurred at each of the time
Figure 2 In vitro secretion of IL-1a (a) and TNF-a (b) by
human monocytes exposed for different time periods to
LPS alone or to LPS plus different concentrations of
moxifloxacin. Combined results of monocytes from the
six responsive donors are shown.
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periods but was most pronounced at the peak of
secretion of this cytokine, i.e. 6 h of exposure. The
reason for the failure of the drug to signiﬁcantly
inhibit TNF-a secretion by monocytes of the other
four donors is unclear. This observation also dif-
fers from what was noted with trovaﬂoxacin [15],
with the streptogramin synercid [4] and with the
macrolide antibiotics azithromycin and clarithro-
mycin [3] which strongly inhibited the secretion
of TNF-a in a dose–response manner. Similar to
results with azithromycin and clarithromycin [3],
moxiﬂoxacin did not have a demonstrable
inhibitory effect on the secretion of TNF-a by
Pansorbin-stimulated monocytes. In contrast,
both trovaﬂoxacin [15] and synercid [4] signiﬁ-
cantly inhibited TNF-a by Pansorbin-stimulated
monocytes.
Our results indicate that moxiﬂoxacin has an
immunomodulatory effect through its capacity to
inhibit the secretion of IL-1a and TNF-a by human
monocytes.
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